BMX-010 is under clinical development by Biomimetix JV and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BMX-010’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BMX-010 is under development for the treatment of pruritus, plaque psoriasis and atopic dermatitis. It is applied topically. The drug candidate is a manganese (III) N-substituted pyridyl porphyrin (MnP)-based SOD mimic. It was also under development for the treatment of type 1 diabetes, rosacea and acne vulgaris.
Biomimetix JV overview
Biomimetix JV (Biomimetix) develops a new class of redox active metalloporphyrin compounds for the treatment of inflammatory skin disease and cancer patients undergoing radiation therapy and chemotherapy. Its pipeline products include BMX-001 targeting high-grade glioma, head and neck cancers, brain metastases, and anal cancer and BMX-010 indicated for the treatment of atopic dermatitis, pruritus (itch), acne, psoriasis, rosacea, and other chronic inflammatory skin conditions. Biomimetix’s compounds modulates key nuclear transcription factors to inhibit inflammatory pathways and also stimulating the production of antioxidants. Biomimetix is headquartered in Greenwood Village, Colorado, the US.
For a complete picture of BMX-010’s drug-specific PTSR and LoA scores, buy the report here.